HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

Also called NCT05623189

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 218 participants (enrolled count) (from the registry)
Sponsor
HighTide Therapeutics (Hong Kong) Limited (from the registry)
Registry
  • NCT NCT05623189
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Hong Kong SAR China, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05623189. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-27 (actual); primary completion 2025-03-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
Acronym
CENTRICITY
Condition
Nonalcoholic Steatohepatitis (NASH)
Intervention (Drug)
HTD1801
Intervention (Drug)
Placebo
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited (class: industry)

Record details

Record id
cardio:ct-nct05623189
Content hash
6873f3d72c5936e256b25646be12c04eede155a5f55dd8e391c760c57de752af